Recognising and treating the diabetic patient in cardiovascular care

European Journal of Cardiovascular Nursing

Volumn 1, Issue 3, 2002, Pages 171-181

  Bartnik, Malgorzata ^a   Malmberg, Klas ^b   Rydén, Lars ^b  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular disease; Coronary artery disease; Diabetes mellitus; Glucose metabolism; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; STATIN;

ACUTE HEART INFARCTION; BLOOD PRESSURE REGULATION; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY STENT; DIABETES MELLITUS; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MORTALITY; NURSE; NURSING; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVASCULARIZATION; REVIEW; SCREENING; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COMORBIDITY; DIABETES COMPLICATIONS; DIABETES MELLITUS; EVIDENCE-BASED MEDICINE; HUMANS; LIFE STYLE; MASS SCREENING; NURSE'S ROLE; PREVALENCE; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 0038167358     PISSN: 14745151     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-5151(02)00034-8     Document Type: Review

References (89)

1. King H., Aubert R.E., Herman W.H. Global burden of diabetes 1995-2025. Prevalence, numerical estimates and projections. Diabetes Care. 21:1998;1414-1431.
2. Boyle J.P., Honeycutt A.A., Narayan V.K.M., et al. Projection of diabetes burden through 2050. Diabetes Care. 24:2001;1936-1940.
3. Rydén L., Malmberg K. Reducing the impact of diabetic heart's increased vulnerability to cardiovascular disease. Dialogues Cardiovasc. Med. 5:2000;5-22.
4. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. JAMA. 241:1979;2035-2038.
5. Stamler J., Vaccaro O., Neaton J.D., Wenworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 16:1993;434-444.
6. Kanters S.D., Banga J.D., Stolk R.P., Algra A. Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis. Vasc Med. 4:1999;67-75.
7. Clark C.M., Perry R.C. Type 2 diabetes and macrovascular disease. Epidemiology and etiology. Am Heart J. 138:1999;330-333.
8. Balkau B., Shipley M., Jarrett R.J., et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. Diabetes Care. 21:1998;360-367.
9. Baron A. Impaired glucose tolerance as a disease. Am J Cardiol. 88:(Suppl):2001;16H-19H.
10. Continho M., Gerstein H.C., Wang Y., Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 22:1999;233-240.
11. Muggeo M., Verlato G., Bonora E., Zoppini G., Corbellini M., de Marco R. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin dependent diabetes mellitus. The Verona Diabetes Study. Circulation. 96:1997;1750-1754.
12. Fuller J.H., Shipley M.J., Rose G., Jarrett R.J., Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. BMJ. 287:1983;867-870.
13. Pyörälä K. Hyperinsulinemia and insulin resistance as predictors of cardiovascular risk. CVD Prev. 3:2000;28-36.
14. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 354:1999;617-621.
15. International Diabetes Federation: diabetes and cardiovascular disease. Time to act. International Diabetes Federation, Brussels, 2001.
16. Lifestyle and risk factors management and use of drug therapies in coronary patients from 15 countries. Eur Heart J. 22:2001;554-572.
17. Haffner S.M., Lehto S., Ronnemaa T., Pyörälä K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 339:1998;229-234.
18. Wood D., De Backer G., Faergeman O., Graham I., Mancia G., Pyörälä K. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Eur Heart J. 19:1998;1434-1503.
19. Mukamal K.J., Nesto R.W., Cohen M.C., et al. Impact of diabetes on long-term survival after acute myocardial infarction, comparability of risk with prior myocardial infarction. Diabetes Care. 24:2001;1422-1427.
20. Lee W.L., Cheung A.M., Cape D., Zinman B. Impact of diabetes on coronary artery disease in women and men: a metaanalysis of prospective studies. Diabetes Care. 23:2000;962-968.
21. Norhammar A.M., Rydén L., Malmberg K. Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. Diabetes Care. 22:1999;1827-1831.
22. Norhammar A., Tenerz Å., Nilsson G., et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 359:2002;2140-2144.
23. Aronson D., Rayfield E.J., Cheseboro J.H. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med. 126:1997;296-306.
24. Woodfield S.L., Lundergan C.F., Reiner J.S., et al. Angiographic findings and outcome in diabetic patients treated with trombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol. 28:1996;1661-1669.
25. Malmberg K., Yusuf S., Gerstein H., et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction. Results of the OASIS (Organisation to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 102:2000;1014-1019.
26. McGiure D.K., Emanuelsson H., Granger C.B., et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study. Eur Heart J. 21:2000;1750-1758.
27. Priori S.G., Aliot E., Blomstrom-Lundquist C., et al. Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J. 22:2001;1374-1450.
28. Malmberg K., Rydén L., Efendic. A randomized study of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction: effects on 1-year mortality. J Am Coll Cardiol. 26:1995;57-65.
29. Malmberg K., Norhammar A., Wedel H., Rydén L. Glucometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long term results from the DIGAMI study. Circulation. 99:1999;2626-2632.
30. Gu K., Cowie C.C., Harris M.I. Diabetes and decline in heart disease mortality in US adults. JAMA. 281:1999;1291-1297.
31. Soläng L., Malmberg K., Rydén L. Diabetes mellitus and congestive heart failure. Eur Heart J. 20:1999;789-795.
32. Amato L., Paolisso G., Cacciatore F., et al. Congestive heart failure predicts the development of noninsulin dependent diabetes mellitus in the elderly. Diab Metab. 23:1997;213-218.
33. Chae C.U., Glynn R.J., Manson J.E., Guralnik J.M., Taylor J.O., Peffer M.A. Diabetes predicts congestive heart failure in the elderly. Circulation. 98:(Suppl I):1998;721.
34. von Bibra H., Hansen A., Dounis V., Bystedt T., Malmberg K., Rydén L. Diastolic myocardial function and myocardial microvasculature reserve improve with intense insulin treatment in type 2 diabetic patients. Diabetologia. 44:2001;68. Abstract 255.
35. Report of the WHO consultation, definition, diagnosis and classification of diabetes mellitus and its complications. Part 1 diagnosis and classification of diabetes mellitus. World Health Organisation, Department of Noncommunicable Disease Surveillance, Geneva, 1999.
36. American Diabetes Association: report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Tests of glycaemia in diabetes. Diabetes Care 1999;22(Suppl 1):S5-19; S32-41.
37. A desktop guide to type 2 diabetes, 1999, International Diabetes Federation (European Region). Diabet Med. 16:1999;716-730.
38. Grundy SM, Howard B, Smith S, Eckel R, Redberg R, Bonow RO. Prevention Conference VI: diabetes and cardiovascular disease, Executive Summary, Conference Proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002;105:2231-9.
39. Edelman D., Edwards L.J., Olsen M.K., et al. Screening for diabetes in an outpatient clinic population. J Gen Intern Med. 17:2002;23-28.
40. Stuart W.P., Wolf B., Macaulay E.M., Cross K.S. Screening for diabetes on a vascular ward: lessons from an audit. J R Coll Surg Edinb. 43:1998;11-12.
41. Smith N.L., Barzilay J.I., Shaffer D., et al. Fasting and 2-hour post challenge serum glucose measures and risk of incident cardiovascular events in the elderly. The Cardiovascular Health Study. Arch Intern Med. 162:2002;209-216.
42. Capes S.D.E., Hunt D., Malmberg K., Gerstein H.C. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 355:2000;773-778.
43. Intensive blood-glucose control with sulphonyureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
44. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub study. Lancet. 355:2000;253-259.
45. Lindholm L.H., Ibsen H., Dahlöf B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 359:2002;1004-1010.
46. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 359:2002;995-1003.
47. Richter B., Berger M. Randomised controlled trials remain fundamental to clinical decision making in type 2 diabetes mellitus: a comment to the debate on randomised controlled trials. Diabetologia. 43:2000;254-258.
48. Wikström G., Malmberg K., Rydén L. Improved knowledge of antidiabetic treatment - a necessity for the modern cardiologist. Eur Heart J. 20:1999;403-405.
49. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology: acute myocardial infarction: pre-hospital and in-hospital management. Eur Heart J 1996;17:43-63.
50. Bertrand M.E., Simoons M.L., Fox K.A.A., et al. Management of acute coronary syndromes without persistent ST segment elevation. Task Force Report. Eur Heart J. 21:2000;1406-1432.
51. Maggioni A.P., Zuanetti G. What is the most effective management of heart failure in diabetic patients? Dialogues Cardiovascular Med. 5:2000;30-34.
52. Thomas K., Ottervanger J., de Boer M., Suryapranata H., Hoorntje J., Zijstra F. Primary angioplasty compared with thrombolysis in acute myocardial infarction in diabetic patients. Diabetes Care. 22:1999;647-649.
53. Hasdai D., Granger C.B., Srivatsa S.S., et al. Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Study. Global use of strategies to open occluded arteries in acute coronary syndromes. J Am Coll Cardiol. 35:2000;1502-1512.
54. Waldecker B., Waas W., Haberbosch W., et al. Type 2 diabetes and acute myocardial infarction. Angiographic findings and results of an invasive therapeutic approach in type 2 diabetic versus nondiabetic patients. Diabetes Care. 22:1999;1832-1838.
55. Influence of diabetes on 5-year mortality and morbidity in a randomised trials comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularisation Investigation (BARI). Circulation. 96:1997;1761-1769.
56. Keefe J.H., Blackstone E.H., Sergeant P., McCallister B.D. The optimal role of coronary revascularization for diabetics. A risk-adjusted long-term study comparing coronary angioplasty and coronary bypass surgery. Eur Heart J. 19:1998;1696-1703.
57. Mehta S., Yususf S., Peters R., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 358:2001;527-533.
58. Otsuka Y., Miyazaki S., Okumura H., et al. Abnormal glucose tolerance, not small vessel diameter, is a determinant of long-term prognosis in patients treated with balloon coronary angioplasty. Eur Heart J. 21:2000;1790-1796.
59. King L.M., Opie L.H. Glucose and glycogen utilisation in myocardial ischemia - changes in metabolism and consequences for the myocyte. Mol Cell Biochem. 180:1998;3-26.
60. Gerstein H.C., Malmberg K., Capes S., Yusuf S. Cardiovascular diseases. Gerstein H.C., Haynes R.B. Evidence-based diabetes care. 2001;488-514 BC Decker Inc, London.
61. Zuanetti G., Latini R., Maggioni A., Franzosi M., Santoro L., Tognioni G. Effect of the ACE-inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation. 96:1997;4239-4245.
62. Effect of enalapril on mortality in severe congestive heart failure. N Engl J Med. 316:1987;1429-1435.
63. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 325:1991;293-302.
64. Malmberg K., Herlitz J., Hjalmarsson A., Rydén L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large-scale studies. Eur Heart J. 10:1989;423-428.
65. Final report of the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321:129-35.
66. Colwell J.A. Aspirin therapy in diabetes. Diabetes Care. 20:(11):1997;1767-1771.
67. Kendall D.M., Bergenstal R.M. Comprehensive management of patients with type 2 diabetes: establishing priorities of care. Am J Manag Care. 7:(Suppl 10):2001;S327-S343.
68. Block P.J., Schoors D., Van Camp G. Substantial variations in clinical outcome following hospitalisation for heart failure. Eur Heart J. 23:2002;597-599.
69. McDonald K., Ledwidge M., Cahill J., et al. Elimination of early hospitalisation in a randomised, controlled trial of multidisciplinary care in a high-risk, elderly heart failure population: the potential contributions of specialist care, clinical stability and optimal angiotensin-converting enzyme inhibitor dose at discharge. Eur J Heart Failure. 3:2001;209-216.
70. Dumbar J., et al. Adherence in chronic disease. Ann Rev Nurs Res. 18:2000;48-90.
71. Suresh V., Harrison R.A., Houghton P., Naqvi N. Standard cardiac rehabilitation is less effective for diabetics. Int J Clin Pract. 55:2001;445-448.
72. Strömberg A. Educating nurses and patients to manage heart failure. Eur J Cardiovascular Nursing. 1:2002;33-40.
73. Adler A., Stratton I., Neil A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36). BMJ. 321:2000;412-419.
74. Hansson L., Zanchetti A., Camuthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 351:1998;1755-1762.
75. Syvanne M., Taskinen M.R. Lipids and lipoproteins as coronary risk factors in non-insulin dependent diabetes mellitus. Lancet. 350:(Suppl 1):1997;S120-S123.
76. Pyörälä K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., Thorgeirsson G. Cholesterol lowering with simwastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simwastatin Survival Study (4S). Diabetes Care. 20:1997;614-620.
77. Goldberg R.B., Mellies M.J., Sacks F.M., et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation. 98:1998;2513-2519.
78. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
79. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 34:1999;410-418.
80. Elkeles R.S. Blood glucose and coronary heart disease. Eur Heart J. 21:2000;1735-1737.
81. Sratton I.M., Adler A.J., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complicatons of type 2 diabetes (UKPDS 35). Brit Med J. 321:2000;405-412.
82. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Task Force Report. Eur Heart J 2001;22:1852-1923.
83. Scottish Intercollegiate Guidelines Network (SIGN). Management of diabetes. A national clinical guideline: management of diabetic cardiovascular disease, Edinburgh, SIGN Publication No. 2001;55:14-20.
84. Clinical Practice Recommendations 2002: standards of medical care for patients with diabetes mellitus. Diabetes Care. 25:(Suppl 1):2002;S33-S49.
85. Tuomilehto J., Lindstrom J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 344:2001;1343-1350.
86. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Diabetes Prevention Program Research Group: reduction in the incdemce of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 346:2002;393-403.
87. Colhun H.M., Dong W., Barakat M.T., Mather H.M., Poulter N.R. The scope for cardiovascular disease risk factor intervention among people with diabetes mellitus in England: a population-based analysis from the Health Surveys for England 1991-94. Diabetic Med. 16:1999;35-40.
88. Bo S., Cavallo-Perin P., Gentile L. Prevalence of patients reaching the targets of good control in normal clinical practice. Diabetes Care. 22:1999;2092.
89. Norhammar A., Malmberg K., Rydén L., Tornvall P., Stenestrand U., Wallentin L. Under utilisation of evidence based treatment - partial explanation for the unfavourable prognosis in diabetic patients with acute myocardial infarction. Circulation. 401:2001;2962A.